Moleculin Biotech (NASDAQ: MBRX) Gets Sales Rating From StockNews.com Analysts

Moleculin Biotech (NASDAQ: MBRX) Gets Sales Rating From StockNews.com Analysts


StockNews.com has initiated coverage on the shares of Moleculin Biotech (NASDAQ: MBRX – Get Assessment) in a research note released to investors on Tuesday. The brokerage has established a “sell” rating on the stock.

NASDAQ: MBRX opened on Tuesday at $ 1.30. Moleculin Biotech has a 1 year low of $ 1.22 and a 1 year high of $ 3.99. The company’s 50-day simple moving average is $ 1.63 and its 200-day simple moving average is $ 1.82. The company has a market capitalization of $ 37.15 million, a PE ratio of -2.20 and a beta of 1.84.

Moleculin Biotech (NASDAQ: MBRX – Get Rating) last released its earnings results on Friday, March 25. The company reported ($ 0.17) earnings per share (EPS) for the quarter, beating analyst consensus estimates of ($ 0.21) by $ 0.04. Equity analysts expect Moleculin Biotech to post EPS -0.94 for the current fiscal year.

Large investors have recently bought and sold shares of the stock. Sigma Planning Corp acquired a new position in Moleculin Biotech in Q4 valued at $ 80,000. Geode Capital Management LLC increased its holdings in Moleculin Biotech by 3.4% in Q3. Geode Capital Management LLC now owns 245,612 shares in the company valued at $ 736,000 after purchasing an additional 8,026 shares during the period. Citadel Advisors LLC increased its holdings in Moleculin Biotech by 174.9% in Q2. Citadel Advisors LLC now owns 38,053 shares in the company valued at $ 140,000 after purchasing an additional 24,210 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Moleculin Biotech in the second quarter valued at $ 94,000. Finally, Virtu Financial LLC acquired a new stake in Moleculin Biotech in Q4 worth $ 87,000. Institutional investors and hedge funds own 10.57% of the company’s shares.

About Moleculin Biotech (Get evaluation)

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant cancers and viruses. Its main drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers that have metastasized to the lungs.

Featured articles



Receive news and ratings for Moleculin Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Moleculin Biotech and related companies with MarketBeat.com’s FREE daily newsletter.

.

Leave a Comment

Your email address will not be published.